Levosimendan ameliorates Cisplatin (cas 15603-27-1)-induced ototoxicity: Rat model

Add time:09/07/2019    Source:sciencedirect.com

ObjectivesCisplatin is employed for chemotherapeutic purposes in several types of adult and pediatric cancer. However, side-effects including nephrotoxicity, ototoxicity, gastrointestinal effects and neuropathy restrict the use of the drug due to their adverse impacts on quality of life. This study aimed to determine whether levosimendan exhibits a protective effect against cisplatin-related ototoxicity in a rat model by means of functional, biochemical and histochemical analysis.

We also recommend Trading Suppliers and Manufacturers of Cisplatin (cas 15603-27-1). Pls Click Website Link as below: cas 15603-27-1 suppliers

Prev:Review articleCisplatin (cas 15603-27-1): The first metal based anticancer drug
Next:ReviewPhytochemicals: Current strategy to sensitize cancer cells to Cisplatin (cas 15603-27-1))